Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Peer Review reports

Original Submission
26 Jul 2013	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
14 Feb 2014	Reviewed	Reviewer Report - Arias Fernando
19 Mar 2014	Reviewed	Reviewer Report - James A McCaul
1 Apr 2014	Author responded	Author comments - Jean-Pascal Machiels
Resubmission - Version 3
1 Apr 2014	Submitted	Manuscript version 3
Resubmission - Version 4
	Submitted	Manuscript version 4
Resubmission - Version 5
	Submitted	Manuscript version 5
3 Jun 2014	Author responded	Author comments - Jean-Pascal Machiels
Resubmission - Version 6
3 Jun 2014	Submitted	Manuscript version 6
Publishing
12 Jun 2014	Editorially accepted
28 Jun 2014	Article published	10.1186/1471-2407-14-473

Back to article page